Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07055282 · ClinicalTrials.gov registry record · Early Phase 1
SGLT2i in Kidney Stones
A Early Phase 1 study of Kidney Stones, sponsored by University of Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07055282: Recruiting Early Phase 1 study of Kidney Stones, sponsored by University of Chicago.
NCT07055282 is a Early Phase 1 study of Kidney Stones that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 32 participants, below the 293-participant average among 15 other Kidney Stones trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07055282, a Early Phase 1 study of Kidney Stones, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e. calcium oxalate or calcium phosphate stones. Previous studies in those without kidney stones found that empagliflozin increased urinary citrate levels without raising urine pH. The investigators are testing whether similar effects occur in people with a history of kidney stones. Participants will take empagliflozin daily for 4 weeks. The investigators will collect 24-hour urine samples before and after treatment to measure various factors that influence stone formation, including citrate levels, pH, and calculated stone formation risk. The investigators will enroll 32 participants: 16 with a history of calcium oxalate stones and 16 with calcium phosphate stones. Results from this study may inform future larger clinical trials investigating empagliflozin as a kidney stone prevention strategy.
Primary Outcome
Calcium phosphate supersaturation will be measured or calculated at baseline and study completion. The investigators will calculate change in calcium phosphate supersaturation for all participants and within each group.
Conditions Studied
Interventions
- DRUG Empagliflozin (Jardiance®)
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2027-12-31 |
| Phase | Early Phase 1 |
What NCT07055282 shows while recruiting
NCT07055282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 293-participant average among 15 other Kidney Stones trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Kidney Stones appearing as the primary indexed condition, and to 1 intervention - of which Empagliflozin (Jardiance®) is the first listed.
NCT07055282 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT07055282 about?
NCT07055282 is a clinical study titled "SGLT2i in Kidney Stones". This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e. calcium oxalate or calcium phosphate stones. Pre...
What is the current status of trial NCT07055282?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2025-11-20. Estimated completion is 2027-12-31.
What conditions does trial NCT07055282 study?
This clinical trial studies the following conditions: Kidney Stones.
What interventions are being tested in trial NCT07055282?
The interventions under investigation include: Empagliflozin (Jardiance®) (DRUG).
Who is sponsoring clinical trial NCT07055282?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07055282 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Stones
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07055282's enrollment target sits among peer trials
32 12th of 15 higher than 4 of 15 other Kidney Stones trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Stones trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fecal Microbiota Transplantation in Kidney Stone Patients
RECRUITING · Early Phase 1
-
Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease
RECRUITING · NA
-
Evaluation of Eye Gaze Sharing in the Operating Room
RECRUITING · NA
-
Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)
RECRUITING · NA
-
CaOx Stone Prevention
RECRUITING · Phase 4
-
Eye Gaze Guidance Evaluation in Phantoms
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI